Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry
| Autor: | Edmund M.T. Lau, Ken Whyte, Eugene Kotlyar, Tanya McWilliams, Nathan Dwyer, David A. Haydock, Michael K. Wilson, Geoff Strange, John Feenstra, Carolyn Corrigan, Dominic Keating, Trevor Williams, James Anderson, Nicholas Collins, David C. McGiffin, Melanie Lavender, Kumud Dhital, Joshua Gold, Rachael Cordina, Jeremy P. Wrobel, Katherine Kearney, Helen Whitford, Anne Keogh, David Boshell |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Multivariate survival analysis medicine.medical_specialty business.industry Hypertension Pulmonary food and beverages Disease Endarterectomy Pulmonary Artery medicine.disease Pulmonary hypertension Pulmonary embolism Pulmonary endarterectomy Treatment Outcome Internal medicine Epidemiology Chronic Disease medicine Humans Chronic thromboembolic pulmonary hypertension Registries Outcome data business Pulmonary Embolism New Zealand |
| Zdroj: | Respirology (Carlton, Vic.)REFERENCES. 26(12) |
| ISSN: | 1440-1843 |
| Popis: | BACKGROUND AND OBJECTIVE Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%-4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically operable disease. The epidemiology and long-term outcomes of CTEPH have not been previously described in Australia and New Zealand. METHODS Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry for patients diagnosed with CTEPH between January 2004 and March 2020. Baseline characteristics, treatment strategies, outcome data and long-term survival are reported. RESULTS A total of 386 patients were included with 146 (37.8%) undergoing PEA and 240 (62.2%) in the non-PEA group. PEA patients were younger (55 ± 16 vs. 62 ± 16 years, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text